Incysus Therapeutics, Inc. announced that data related to the Company’s ongoing programs will be presented at the 60th American Society of Hematology Annual Meeting & Exposition (ASH) and at the 6th annual Haploidentical Transplant Symposium (HAPLO2018) this week in San Diego, CA.

Link

Incysus Therapeutics, Inc. announced that Lawerence S. Lamb, PhD, a Scientific Co-Founder of Incysus will present a poster during the 23rd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in New Orleans. The preclinical data demonstrates that Incysus’ technology using gene-modified γδ T cells, in combination with checkpoint inhibitor antibodies has the potential to drive synergies to increase immune mediated killing of glioblastoma.

Link

Incysus Therapeutics, Inc. announced that William Ho, President and Chief Executive Officer will join a distinguished group of panelists including representatives from Merck, Bristol-Myers Squibb, Quentis Therapeutics and Memorial Sloan-Kettering Cancer Center during the “Therapeutic Insight: Immuno-Oncology’s Next Generation Therapies” panel at the 2018 Life Sciences Summit

Link

Incysus Therapeutics, Inc. announced that William Ho, a Co-Founder of Incysus, President and CEO will present a company overview at the annual BIO Investor Forum conference being held in San Francisco. The presentation will be on Thursday, October 18, 2018 at 10:15am PDT in the Elizabethan A room at the Westin St. Francis Hotel.

Link

Incysus Therapeutics, Inc. announced that Lawrence Lamb, PhD, a Scientific Co-Founder of Incysus, will present at a scientific symposium today, on Thursday, August 16, 2018 during the 10th Annual Bioprocessing Summit, in Boston, Massachusetts. The discussion will focus on the scale-up and GMP manufacturing of gene-modified γδ T cells for a Phase I trial.

Link

Incysus Therapeutics, Inc. announced that Lawrence Lamb, PhD, a Scientific Co-Founder of Incysus, will present at a scientific symposium on June 10, 2018 during the 8th International Gamma-Delta T Cell Conference, in Bordeaux, France. Dr. Lamb’s session is titled: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a rational therapeutic design for elimination of minimal residual primary high grade gliomas”.

Link

Incysus, Ltd. announced that effective May 7, 2018 it had moved its corporate domicile from Bermuda to the United States of America in the State of Delaware. Advancing ahead, the corporate name will now be Incysus Therapeutics, Inc. Management expects that these changes will help support our growth strategy without affecting the day-to-day business and operations of the organization.

Link

Dr. Lamb and Dr. Maus will Co-Chair a Symposium Titled: “Tipping Point: Gene Therapy Entering the Market” on Friday, May 18, 2018 at 8:00am CDT at the American Society of Gene and Cell Therapy (ASGCT) Meeting in Chicago. Dr. Bruce Levine, PhD, also member of Incysus’ Scientific Advisory Board will also present during the session.

Link

Joy E. Bessenger has been appointed Senior Vice President, Finance and Strategy to help Incysus advance through its next stage of growth as it prepares to initiate clinical programs in 2018

Link

William Ho, Chief Executive Officer of Incysus will present at the 25th Annual BioCentury Future Leaders Conference on Friday, March 23, 2018 at 2:30pm EDT at the Millennium Broadway Hotel and Conference Center in New York

Link

Dr. Lawrence Lamb, to Present Adoptive Gamma-Delta T cell Immunotharpy as a Strategy for Eliminating Residual Malignancy at CAR-T Congress USA Meeting in Boston

Link

Dr. Lawrence Lamb, PhD to present at a Plenary Session of the Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy, a special AACR conference being held in San Diego, California

Link

IND to support Phase 1 safety and activity study of Drug Resistant Immunotherapy for the treatment of glioblastoma.

Link